Semaglutide
Indications
| Indication | Brand / Formulation | Approved Population | Status |
|---|---|---|---|
| Type 2 diabetes mellitus — adjunct to diet and exercise to improve glycemic control | Ozempic SC; Rybelsus oral | Adults | FDA Approved |
| Cardiovascular risk reduction in T2DM — reduce risk of MACE (CV death, nonfatal MI, nonfatal stroke) | Ozempic SC; Rybelsus oral | Adults with T2DM and established cardiovascular disease | FDA Approved |
| Diabetic kidney disease — reduce risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death | Ozempic SC | Adults with T2DM and chronic kidney disease | FDA Approved (Jan 2025) |
| Chronic weight management — adjunct to a reduced-calorie diet and increased physical activity | Wegovy SC; Wegovy oral 25 mg | Adults with obesity (BMI ≥30 kg/m²) OR adults with overweight (BMI ≥27 kg/m²) and at least one weight-related comorbidity | FDA Approved |
| Adolescent obesity — adjunct to a reduced-calorie diet and increased physical activity | Wegovy SC | Pediatric patients aged ≥12 years with obesity (BMI ≥95th percentile for age and sex) | FDA Approved (2022) |
| Additional weight reduction beyond 2.4 mg — for adults tolerating 2.4 mg for ≥4 weeks who require further weight loss | Wegovy HD SC 7.2 mg | Adults with obesity or overweight with at least one weight-related condition | FDA Approved (Mar 2026) |
| Cardiovascular risk reduction in non-diabetic patients — reduce risk of MACE | Wegovy SC; Wegovy oral 25 mg | Adults with established cardiovascular disease and either obesity or overweight | FDA Approved (Mar 2024) |
| Noncirrhotic MASH with moderate-to-advanced fibrosis — improvement of MASH and fibrosis (consistent with stage F2–F3) | Wegovy SC 2.4 mg | Adults with noncirrhotic MASH and stage F2–F3 fibrosis | FDA Accelerated (Aug 2025) |
Semaglutide carries the broadest set of FDA-approved indications among GLP-1 receptor agonists, covering glycemic control, cardiovascular risk reduction, kidney protection, weight management, and — most recently — chronic liver disease. The 2026 ADA Standards of Care position GLP-1 receptor agonists with proven cardiorenal benefit (semaglutide and dulaglutide) as preferred first-line agents in patients with type 2 diabetes who have established ASCVD, heart failure, or chronic kidney disease, regardless of HbA1c or background metformin use. In adults with overweight or obesity and ASCVD, semaglutide 2.4 mg has the strongest evidence among GLP-1 RAs for cardiovascular event reduction (SELECT trial).
Heart failure with preserved ejection fraction (HFpEF) and obesity: The STEP-HFpEF and STEP-HFpEF DM trials demonstrated significant improvements in heart failure symptoms (KCCQ-CSS), 6-minute walk distance, and weight loss with semaglutide 2.4 mg in patients with obesity-phenotype HFpEF. As of early 2026, no major US heart-failure guideline has formally incorporated this indication; semaglutide 2.4 mg is not FDA-labelled for HFpEF. Evidence quality: high (RCT-level), regulatory status: not yet labelled.
Polycystic ovary syndrome with obesity / metabolic phenotype: Used to address the metabolic and weight-related features of PCOS. Insulin sensitization and weight loss may also improve menstrual regularity and ovulation. Counsel about the potential return of fertility on weight loss. Evidence quality: low–moderate.
Substance use disorder (alcohol, nicotine, opioids): Active area of research with phase 2/3 trials underway based on observational signal of reduced cravings; not yet FDA-approved. Evidence quality: low (mostly observational and early-phase).
Dosing
Semaglutide is dosed by clinical scenario, not by tablet/pen strength. The defining dosing principle is gradual escalation — most gastrointestinal intolerance occurs during titration, and the discipline to escalate slowly and to delay escalation if symptoms are not yet under control is the single biggest determinant of long-term tolerability.
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Type 2 diabetes — glycemic control (Ozempic SC) | 0.25 mg SC once weekly × 4 weeks | 0.5 mg, 1 mg, or 2 mg SC once weekly | 2 mg SC once weekly | Escalate to 0.5 mg after 4 weeks; if additional control needed, increase to 1 mg after at least 4 more weeks; further escalation to 2 mg only after at least 4 weeks at 1 mg 0.25 mg is a starting dose only — not effective for glycemic control |
| Type 2 diabetes + established CVD — MACE reduction (Ozempic SC) | Same titration as above | 0.5 mg, 1 mg, or 2 mg SC once weekly | 2 mg SC once weekly | SUSTAIN-6 demonstrated MACE reduction at 0.5–1 mg Add to standard CV risk-reduction therapy (statin, antihypertensives, antiplatelet as indicated) |
| Type 2 diabetes + chronic kidney disease (Ozempic SC, FLOW indication) | 0.25 mg SC once weekly × 4 weeks | 1 mg SC once weekly | 1 mg SC once weekly | FLOW-trial dose. Escalate 0.25 → 0.5 mg after 4 weeks, then 0.5 → 1 mg after at least 4 more weeks 2 mg has not been studied in the kidney-outcomes trial |
| Adult chronic weight management — SC (Wegovy) | 0.25 mg SC once weekly × 4 weeks | 2.4 mg SC once weekly (or 1.7 mg if 2.4 not tolerated) | 2.4 mg SC once weekly (or 7.2 mg with Wegovy HD; see below) | Per the FDA-labelled escalation: 0.25 → 0.5 → 1 → 1.7 → 2.4 mg, each step held for 4 weeks. If a dose is not tolerated, hold for an additional 4 weeks before re-trying If the 2.4 mg dose is intolerable, the dose may be temporarily decreased to 1.7 mg for up to 4 weeks before re-attempting 2.4 mg; discontinue if 2.4 mg is not tolerated |
| Additional weight reduction (Wegovy HD SC) | Patient must have tolerated 2.4 mg for ≥4 weeks | 7.2 mg SC once weekly | 7.2 mg SC once weekly | Step up directly from 2.4 mg to 7.2 mg in patients with adequate tolerance who require further weight loss Increased frequency of dysesthesia / altered skin sensation compared with 2.4 mg (~22% vs ~6%) — counsel patients |
| Adolescent obesity (≥12 years) — SC (Wegovy) | 0.25 mg SC once weekly × 4 weeks | 2.4 mg SC once weekly (or 1.7 mg if 2.4 not tolerated) | 2.4 mg SC once weekly | Same titration schedule as adults. Dietitian and adolescent-medicine support recommended Wegovy HD 7.2 mg is approved for adults only |
| CV risk reduction with overweight/obesity — SC (Wegovy) | Same titration as weight management above | 1.7 mg or 2.4 mg SC once weekly | 2.4 mg SC once weekly | SELECT trial evaluated 2.4 mg dose Add to optimal cardiovascular pharmacotherapy |
| Noncirrhotic MASH with F2–F3 fibrosis — SC (Wegovy) | Same titration as weight management above | 2.4 mg SC once weekly (1.7 mg if 2.4 not tolerated) | 2.4 mg SC once weekly | ESSENCE-trial dose. Continued approval is contingent on confirmatory trial data (Part 2 expected 2029) Do not initiate in cirrhotic patients (efficacy/safety not established at the time of approval) |
| Type 2 diabetes — oral (Rybelsus) | 3 mg PO once daily × 30 days | 7 mg or 14 mg PO once daily | 14 mg PO once daily | 3 mg is a starting dose only — not effective for glycemic control. Increase to 7 mg after 30 days; if needed, increase to 14 mg after at least 30 more days Newer “formulation R2” tablets are 1.5, 4, and 9 mg; the prescribing information provides switching guidance between original and R2 strengths |
| Chronic weight management — oral (Wegovy tablets 25 mg) | 1.5 mg PO once daily × 30 days | 25 mg PO once daily | 25 mg PO once daily | Stepwise escalation 1.5 → 4 → 9 → 25 mg, each step held for 30 days as tolerated First oral GLP-1 RA approved for weight management (Dec 2025, OASIS-4 trial). If 25 mg is not tolerated, consider switching to Wegovy injection 1.7 mg |
| Switching SC ↔ oral semaglutide | Per the FDA prescribing information: from Ozempic to Rybelsus, follow the brand-specific switching guidance in the Rybelsus 2024 PI update; from Wegovy 2.4 mg injection to Wegovy 25 mg tablets, initiate the tablet 1 week after the last injection; from Wegovy 25 mg tablets to Wegovy 2.4 mg injection, initiate the day after the last tablet | Equivalence is not strictly 1:1 between SC and oral exposure; semaglutide blood concentrations from Wegovy 25 mg tablets are similar to Wegovy 2.4 mg injection in patients without T2DM and lower in patients with T2DM No washout required when switching | ||
| Missed dose — SC weekly | If <5 days late: take as soon as possible | If >5 days late: skip; resume on next scheduled day | — | The day of the week may be changed if needed, provided ≥48 hours have elapsed between doses |
| Missed dose — oral daily | Skip the missed dose; resume the next morning | — | — | Do not double up. Reinforce the fasting + 30-minute wait counselling that often gets relaxed over time |
Population-Specific Adjustments
| Population | Adjustment | Notes |
|---|---|---|
| Renal impairment (any eGFR, including dialysis) | No specific dose adjustment | Semaglutide pharmacokinetics not clinically affected by renal function. However, monitor for AKI from dehydration during GI side effects, and apply the CKD-specific 1 mg dose ceiling when using Ozempic for the FLOW (CKD) indication |
| Hepatic impairment (any severity, including Child-Pugh C) | No specific dose adjustment | PK studies show no clinically relevant change with hepatic impairment |
| Older adults (≥65 y) | No specific dose adjustment | Reasonable to escalate more slowly given higher AKI/dehydration risk and frailty considerations; consider muscle-mass preservation strategies (resistance training, adequate protein intake) |
| Pediatric <12 years | Not approved for any indication | Safety and efficacy not established |
| Pediatric 12–17 years | Wegovy SC weight-management indication only (≥12 y with obesity) | Other formulations and indications not approved in this age group |
| Pregnancy | Discontinue when pregnancy is recognized; based on animal data, potential risk to fetus; weight loss provides no benefit during pregnancy and may cause harm | |
| Reproductive-age women planning pregnancy | Counsel on contraception and pre-conception planning | Per the Wegovy and Ozempic prescribing information, discontinue at least 2 months before a planned pregnancy because of the long elimination half-life |
| Surgery / general anesthesia | Individualized; share decision-making | The 2024 multi-society guidance (ASA, AGA, ASMBS, ISPCOP, SAGES) recommends that most patients can continue GLP-1 RAs before elective procedures, with risk stratification: highest-risk patients (those still escalating dose, those with significant ongoing GI symptoms, or those undergoing high-aspiration-risk procedures) should follow a 24-hour clear-liquid diet before the procedure or have the medication held. The earlier 2023 ASA guidance had recommended holding ~1 week before SC weekly dosing or the day of the procedure for daily oral dosing; the 2024 update softens this in favour of risk stratification |
Oral semaglutide bioavailability is <1% and depends entirely on co-formulated salcaprozate sodium (SNAC), which transiently increases gastric absorption. To achieve any therapeutic effect, the tablet must be taken: (1) on an empty stomach — first thing on awakening, with no food, drink, or other oral medication preceding it; (2) with no more than 4 ounces (120 mL) of plain water — milk, juice, coffee, and even carbonated water all reduce absorption; (3) swallowed whole — do not split, crush, or chew; (4) followed by at least 30 minutes of fasting before any food, drink (other than plain water), or oral medication. Patients who relax these rules typically lose efficacy without realizing why. Reinforce these instructions at every refill.
The single most common reason semaglutide “fails” is premature discontinuation during titration for nausea or vomiting. The first move when GI symptoms become bothersome is to delay the next escalation step by another 4 weeks, not to stop the drug. The second move is to step down one level (e.g., from 1.7 mg back to 1 mg, or from 2.4 mg to 1.7 mg) and stay there as the maintenance dose for up to 4 weeks before re-attempting escalation. Per the Wegovy PI, the drug should be discontinued if the 2.4 mg dose cannot be tolerated. Counsel patients up front that some nausea during titration is expected and is not a reason to stop unsupervised.
Pharmacology
Mechanism of Action
Semaglutide is a long-acting peptide analog of glucagon-like peptide-1 (GLP-1) with 94% sequence homology to native human GLP-1. Three structural modifications confer its prolonged half-life and oral bioavailability potential: (1) substitution at position 8 (Aib for Ala) provides resistance to dipeptidyl peptidase-4 (DPP-4) cleavage; (2) a hydrophilic spacer and C18 fatty di-acid attached to position 26 lysine enable strong reversible binding to serum albumin (>99%), reducing renal clearance and protecting against further peptidase degradation; (3) a minor change at position 34 ensures attachment of only one fatty di-acid. The molecule binds and activates the GLP-1 receptor with similar affinity to native GLP-1 but persists at receptors for days rather than minutes.
GLP-1 receptors are expressed on pancreatic β-cells, α-cells, gastric smooth muscle, vagal afferents, and neurons in appetite-regulating regions of the brainstem and hypothalamus. Activation produces a coordinated set of effects: (1) glucose-dependent insulin secretion from β-cells with proportional restoration of first-phase insulin response in T2DM; (2) suppression of glucagon from α-cells when glucose is elevated, reducing hepatic glucose output; (3) delayed gastric emptying, which slows postprandial glucose excursion and prolongs satiety; (4) central appetite suppression via direct receptor activation in appetite-regulating brain regions, reducing food intake and altering food preferences. The glucose-dependence of insulin secretion explains why semaglutide causes minimal hypoglycemia as monotherapy. The CV and renal benefits demonstrated in SUSTAIN-6, SELECT, and FLOW are not fully explained by glycemic or weight effects alone and likely involve direct vascular, anti-inflammatory, and natriuretic actions.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | SC: bioavailability ~89%; absorption similar from abdomen, thigh, and upper arm; Tmax 1–3 days. Oral: bioavailability <1%; SNAC transiently enhances gastric absorption; food and water beyond ~4 oz markedly reduce exposure | SC delivery is reliable and forgiving of timing; oral delivery is highly sensitive to administration technique. Steady-state plasma exposure varies by dose and formulation: ~65 ng/mL (Ozempic 0.5 mg/wk) and ~123 ng/mL (Ozempic 1 mg/wk) per the FDA PI; ~75 nmol/L (Wegovy 2.4 mg/wk) |
| Distribution | Apparent volume of distribution after SC ~12.5 L; protein binding >99% (predominantly albumin via the C18 fatty di-acid anchor); crosses placenta in animal studies | The high albumin binding underlies the long half-life and means very few free-drug interactions are clinically relevant |
| Metabolism | Proteolytic cleavage of the peptide backbone and sequential β-oxidation of the C18 fatty-acid side chain; not a CYP450 substrate, inhibitor, or inducer | Pharmacokinetic interactions are minimal at the metabolic level. Clinically relevant interactions arise from delayed gastric emptying affecting absorption of co-administered oral drugs and, for the oral formulations, from disruption of SNAC-mediated gastric uptake |
| Elimination | Half-life ~1 week (~165 hours), supporting once-weekly SC dosing and once-daily oral dosing; primary excretion routes are urine and feces; ~3% of an absorbed dose is excreted unchanged in urine; renal impairment (including ESKD on dialysis) does not clinically alter exposure | Steady state is reached after 4–5 weeks of weekly SC dosing; full effect on weight, A1c, or other endpoints unfolds over 3–6+ months. After discontinuation, plasma concentrations decline over approximately 5–7 weeks (effective washout) |
Side Effects
The semaglutide adverse-reaction profile is dominated by gastrointestinal symptoms that emerge during titration and abate with dose stabilization or step-back. Serious events (pancreatitis, gallbladder disease, AKI from dehydration, diabetic retinopathy progression, pulmonary aspiration during anesthesia, hypersensitivity) are uncommon but require recognition. Frequencies below are drawn from the FDA prescribing information for the relevant brand and indication; rates differ across formulations and indications because doses differ.
| Adverse Effect | Approximate Incidence | Clinical Note |
|---|---|---|
| Nausea | Wegovy 2.4 mg: 44% vs 16% placebo lower rates with Ozempic 0.5–1 mg | Almost always emerges during titration; usually mild–moderate; managed with slow escalation, smaller meals, avoiding fatty/spicy foods, and dose hold or step-down if persistent |
| Diarrhea | Wegovy 2.4 mg: 30% vs 16% placebo | Often co-occurs with nausea; usually self-limited; rule out other causes (gastroenteritis, antibiotics, lactose) if persistent or severe |
| Vomiting | Wegovy 2.4 mg: 25% vs 6% placebo | Higher rates at higher doses; risk of dehydration and AKI if severe; consider antiemetics, dose hold, hydration |
| Constipation | Wegovy 2.4 mg: ~24% | Counter-intuitive but common — secondary to delayed gastric and intestinal motility plus reduced food/fluid intake; address with hydration, fibre, stool softeners |
| Abdominal pain / discomfort | Wegovy 2.4 mg: ~20% | Usually mild; persistent or severe abdominal pain warrants evaluation for pancreatitis or gallbladder disease |
| Dysesthesia / altered skin sensation (Wegovy HD 7.2 mg) | ~22% with 7.2 mg vs ~6% with 2.4 mg, ~0.3% with placebo (STEP UP trial) | Includes paresthesia, hyperesthesia, sensitive skin, burning sensation; typically self-limited; FDA is conducting further investigation; counsel patients in advance |
| Adverse Effect | Approximate Incidence | Clinical Note |
|---|---|---|
| Headache | ~7–14% | Usually mild; often associated with reduced caloric intake or dehydration during early titration |
| Fatigue | ~5–11% | Frequently reflects reduced caloric intake; counsel on adequate protein and hydration |
| Dyspepsia / GERD / eructation | ~3–9% | Related to delayed gastric emptying; PPIs or H2 blockers can be added if symptoms are bothersome |
| Abdominal distension / flatulence | ~5–7% | Usually improves with dose stabilization |
| Dizziness | ~3–8% | Often related to volume depletion or hypoglycemia (when on insulin/secretagogues); check orthostatic vitals |
| Hypoglycemia (with insulin or secretagogues) | Increased risk | Reduce the secretagogue or insulin dose at semaglutide initiation; intensify SMBG counselling |
| Injection site reactions (SC formulations) | Wegovy: ~1.4% (vs ~1% placebo) | Usually transient erythema, pruritus, induration, or irritation; rotate sites within the chosen body region |
| Cholelithiasis / cholecystitis | ~1–3% | Associated with rapid weight loss; counsel on RUQ pain warning signs |
| Heart rate increase | Mean ~1–4 bpm | Usually clinically inconsequential; assess in patients with palpitations or relevant history |
| Alopecia (Wegovy) | ~3% with Wegovy vs ~1% placebo | Likely related to rapid weight loss (telogen effluvium); typically reversible; counsel on adequate protein |
| Lipase / amylase elevation (without pancreatitis) | Mean lipase +39%, amylase +16% (Wegovy) | Rarely reaches clinically significant levels; routine baseline lipase/amylase is not recommended due to high background variability |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Acute pancreatitis | Uncommon (post-marketing & trial reports) | Any time during therapy | Discontinue promptly if pancreatitis is suspected; check lipase/amylase, imaging; do not restart if confirmed; consider an alternative class |
| Acute kidney injury / worsening of CKD | Uncommon; mostly in setting of dehydration from GI side effects | During GI illness or rapid escalation | Maintain hydration; hold semaglutide during GI illness with reduced fluid intake; check creatinine; restart when stable |
| Diabetic retinopathy progression (T2DM) | SUSTAIN-6: 3.0% vs 1.8% placebo (HR 1.76; 95% CI 1.11–2.78) | Within first months of glucose lowering, especially with rapid A1c reduction in patients with pre-existing retinopathy | Baseline retinal exam in patients with known retinopathy; retinal monitoring during initiation; gradual A1c lowering. Most events relate to magnitude/rapidity of A1c reduction in patients with pre-existing retinopathy |
| Pulmonary aspiration during anesthesia / deep sedation | Post-marketing reports | Around procedures requiring deep sedation or general anesthesia | Inform every anesthesia provider; apply 2024 multi-society guidance — most patients can continue with risk stratification (24-h liquid diet for highest-risk; consider holding ~1 week before procedure for SC weekly dosing in highest-risk cases per the 2023 ASA guidance) |
| Severe gastrointestinal adverse reactions (Section 5.7 Ozempic / 5.6 Rybelsus / Wegovy PI) | Uncommon; emphasized in 2024–2025 PI updates | Any time | Discontinue if patient develops severe persistent abdominal pain, intractable vomiting, gastroparesis-like syndrome, ileus; rule out other causes |
| Hypersensitivity (anaphylaxis, angioedema) | Rare | Usually within first weeks; can occur later | Discontinue permanently; standard hypersensitivity management; document allergy |
| Acute gallbladder disease (cholecystitis, biliary obstruction) | Uncommon (occurred in clinical trials) | During rapid weight loss | Imaging if RUQ symptoms; surgical consult if confirmed; semaglutide can usually be continued unless surgery is imminent |
| Suicidal ideation / behavior (signal under regulatory surveillance) | Not confirmed in large pharmacoepidemiologic studies; FDA and EMA continue surveillance | Any time | Counsel patients/caregivers to monitor for new or worsening depression, mood changes, or suicidal ideation; review at follow-up visits |
| Medullary thyroid carcinoma (theoretical, boxed warning) | Unknown human risk; rodent C-cell tumors at clinically relevant exposures | Theoretical; long-term | Contraindicated in personal/family history of MTC or MEN 2; counsel on neck mass, dysphagia, persistent hoarseness, dyspnea; per the FDA PI, routine calcitonin or thyroid ultrasound surveillance is NOT recommended |
| Reason for Discontinuation | Frequency | Context |
|---|---|---|
| Persistent or severe GI intolerance despite step-down and slow titration | Most common reason | Try step-down or restart with longer titration intervals before permanent discontinuation |
| Acute pancreatitis (confirmed) | Uncommon | Permanent discontinuation; document reaction; alternative class |
| Pregnancy (planned or recognized) | As applicable | Discontinue ≥2 months before planned conception due to long half-life; switch to insulin if T2DM |
| Major surgery / extended NPO status (highest-risk patients) | Procedure-driven | Usually a hold rather than permanent discontinuation; individualized per the 2024 multi-society guidance |
| Hypersensitivity reaction | Rare | Permanent; no rechallenge |
| Suspected new MTC or thyroid nodule | Rare | Permanent discontinuation pending workup; endocrinology referral |
The 2024–2025 FDA label updates (Section 5.7 for Ozempic; Section 5.6 for Rybelsus; equivalent section in Wegovy) explicitly emphasize severe GI reactions: persistent severe abdominal pain, intractable vomiting, dehydration, ileus, and gastroparesis-like syndromes. Practical approach: (1) during routine titration, mild–moderate nausea is expected and managed with slow escalation, smaller meals, and avoiding triggers; (2) persistent symptoms beyond 4–6 weeks at a stable dose warrant a step-down or extended hold, plus evaluation for alternative causes (gallbladder disease, medication, infection); (3) severe symptoms — refractory vomiting, dehydration, signs of ileus or gastroparesis — require discontinuation, hydration, and workup; (4) any patient who develops persistent severe abdominal pain needs lipase, transaminases, and imaging to evaluate for pancreatitis or biliary disease before resuming therapy.
Drug Interactions
Semaglutide is not a CYP450 substrate, inhibitor, or inducer, so traditional metabolic drug-drug interactions are minimal. The clinically meaningful interactions are: (1) pharmacodynamic synergy with insulin and insulin secretagogues that increases hypoglycemia risk; (2) delayed gastric emptying, which can alter the absorption of co-administered oral drugs (most studies show no clinically significant change with the SC formulation, but the oral semaglutide tablet has been shown to increase levothyroxine exposure by 33% per the FDA PI); and (3) co-administration of food, drink, or other oral medications with oral semaglutide disrupts the SNAC-mediated gastric absorption and reduces semaglutide exposure.
Monitoring
Routine monitoring on semaglutide is light and indication-driven: response to therapy (HbA1c, weight, liver outcomes), surveillance for pancreatic and biliary complications, and renal function during GI illness or volume depletion.
-
HbA1c (T2DM indications)
Every 3 months until at goal; every 6 months once stable
Routine Expected reduction with Ozempic 0.5–2 mg or Rybelsus 7–14 mg is approximately 1.0–1.8% from baseline. ADA target is generally <7%, individualized by life expectancy, hypoglycemia risk, and frailty. -
Body Weight (weight-management and MASH indications)
Each visit; review at maintenance dose
Routine Per FDA labelling, evaluate response to chronic weight management. Pivotal-trial mean weight loss: Wegovy 2.4 mg ~14.9% (STEP 1, 68 weeks), Wegovy HD 7.2 mg ~20.7% (STEP UP, 72 weeks, trial product estimand), Wegovy 25 mg tablets ~13.6% (OASIS-4, 64 weeks, treatment policy estimand; 16.6% with full adherence). Reconsider therapy if substantially less response than expected at maintenance dose. -
Renal Function (eGFR, creatinine)
Baseline; with intercurrent GI illness; periodic in CKD
Trigger-based Most AKI events have occurred in patients with severe GI side effects causing dehydration. Reinforce sick-day rules and check creatinine after any episode of severe vomiting or diarrhea. -
Lipase / Amylase
Symptom-driven only
Trigger-based Routine baseline lipase/amylase is not recommended (high false-positive rate; mean rises of ~16% amylase and ~39% lipase observed without pancreatitis). Order if persistent severe abdominal pain raises clinical suspicion of pancreatitis. -
Diabetic Retinopathy Examination (T2DM)
Baseline if known retinopathy; per ADA otherwise
Routine Patients with pre-existing diabetic retinopathy should be monitored for progression during the first 6–12 months of glucose lowering, especially with rapid A1c drops. Consider gradual titration in patients with high baseline A1c and active retinopathy. -
TSH / Free T4 (in patients on levothyroxine)
After initiation of oral semaglutide; after switching SC ↔ oral
Trigger-based Oral semaglutide tablets increase levothyroxine exposure by 33% per the FDA PI. Reassess thyroid function 6–8 weeks after starting Rybelsus or Wegovy tablets in patients on levothyroxine. -
Liver Tests (MASH indication)
Baseline; periodically during therapy; per hepatology
Routine For the MASH indication, ALT/AST trends, FIB-4, transient elastography, and (in select cases) repeat biopsy guide ongoing assessment per hepatology recommendations. -
Heart Rate and Blood Pressure
Each visit
Routine Mean increase in heart rate of approximately 1–4 bpm; usually clinically silent. BP commonly improves with weight loss; reassess antihypertensive regimen, especially if symptomatic hypotension or orthostasis emerges. -
“Sick Day” Counselling
Reinforce at every visit
Routine Hydration, hold of ACEi/ARB/diuretics/NSAIDs/metformin during severe vomiting or diarrhea, and a low threshold for clinical contact during prolonged illness. The most common preventable AKI scenario. -
Mental Health / Suicidal Ideation
Each visit, particularly during titration
Routine Although large pharmacoepidemiologic studies have not confirmed an increased suicide risk, counsel patients and families to monitor for new or worsening depression or suicidal ideation, particularly during initiation; document brief mood screening. -
Thyroid Symptom Surveillance
History at each visit
Routine Counsel on neck mass, dysphagia, dyspnea, persistent hoarseness. Per the FDA PI, routine calcitonin or thyroid ultrasound surveillance is NOT recommended in asymptomatic patients (low specificity, risk of unnecessary procedures). -
Body Composition / Sarcopenia (especially older adults)
Periodic clinical assessment
Routine A substantial proportion of weight lost during rapid weight reduction is lean mass; counsel on adequate protein intake (~1.0–1.2 g/kg/day) and resistance training to preserve muscle and function.
Contraindications & Cautions
In rodents (mice and rats), semaglutide causes a dose- and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) at clinically relevant plasma exposures. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
Semaglutide (Ozempic, Wegovy, Rybelsus) is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients on the potential risk of MTC and the symptoms of thyroid tumors (a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with semaglutide and may increase the risk of unnecessary procedures.
Absolute Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity reaction to semaglutide or any product excipient (including SNAC for oral formulations)
Relative Contraindications (Avoid or Specialist Input Required)
- History of pancreatitis — not an absolute contraindication, but use cautiously; consider an alternative class. Discontinue immediately if pancreatitis is suspected; do not restart if confirmed
- Severe gastroparesis or other significant gastric motility disorder — semaglutide further delays gastric emptying and may worsen symptoms
- Active or significant diabetic retinopathy — gradual A1c lowering and retinal monitoring; SUSTAIN-6 showed increased retinopathy progression with semaglutide
- Pregnancy — discontinue when pregnancy is recognized; weight loss is not appropriate during pregnancy and may cause fetal harm
- Cirrhosis (for the MASH indication specifically) — efficacy and safety not established at the time of approval; not labelled for cirrhotic MASH
- Type 1 diabetes mellitus — not studied for glycemic control; semaglutide is not a substitute for insulin in type 1 diabetes or DKA
Use with Caution
- Older adults (≥65 y), particularly those who are frail or sarcopenic — slower titration; emphasis on protein intake and resistance training; monitor renal function during illness
- Patients on insulin or sulfonylureas — reduce these agents at semaglutide initiation to manage hypoglycemia risk
- Patients undergoing elective surgery or procedures with deep sedation/general anesthesia — apply 2024 multi-society guidance with risk stratification (continue for most patients; 24-h liquid diet or hold for highest-risk situations)
- Patients with cholelithiasis — counsel on biliary symptoms; consider gallbladder imaging if RUQ symptoms develop
- Patients with depression or suicidal ideation history — although causality is unconfirmed, counsel and monitor mood, especially during titration
- Lactation — limited human data; risk-benefit decision per individual circumstances
- Reproductive-age women — counsel on effective contraception; discontinue ≥2 months before planned conception
Semaglutide should be discontinued when pregnancy is recognized. For weight management indications, weight loss provides no benefit during pregnancy and may cause fetal harm; for diabetes indications, switch to insulin promptly. Because of the long half-life (~1 week) and washout of approximately 5–7 weeks, women planning pregnancy should be advised to discontinue semaglutide at least 2 months before attempting conception per the Wegovy and Ozempic prescribing information. Human lactation data are limited; molecular weight and high protein binding likely limit transfer into breast milk, but no clinical safety data are available — risk-benefit should be discussed individually.
Patient Counselling
Purpose of Therapy
Frame semaglutide differently depending on indication. For type 2 diabetes, it is a once-weekly injection or once-daily pill that helps the body release insulin when blood sugar is high, reduces sugar production by the liver, and slows digestion — leading to better blood sugar control and often weight loss. For weight management, it is a long-term tool that works on the brain’s appetite-regulating regions to reduce hunger and food preoccupation, supporting sustained weight loss when paired with a reduced-calorie diet and increased activity. For cardiovascular indications, it reduces the risk of heart attack, stroke, and cardiovascular death; for chronic kidney disease, it slows progression of kidney function loss; and for MASH, it reduces liver inflammation and scarring. Across all indications, the medicine works best when continued long term — most patients regain weight and lose other benefits if they stop.
How to Take
For weekly subcutaneous injections (Ozempic, Wegovy), patients self-inject under the skin of the abdomen, thigh, or upper arm — same day each week, any time of day, with or without meals. They should rotate sites within the chosen body region. The pen is single-patient use; never share pens, even with a needle change, due to bloodborne infection risk. For oral tablets (Rybelsus, Wegovy tablets), the timing rules are strict: take first thing on awakening, on a completely empty stomach, with no more than 4 ounces of plain water; swallow whole; wait at least 30 minutes before any food, drink, or other oral medication. Many patients lose efficacy because these rules drift over time — reinforce them at every refill. Counsel patients that GI side effects are most common during dose escalation and usually improve as the body adjusts; the goal is to escalate slowly, not to stop early.
Sources
- U.S. Food and Drug Administration. Ozempic (semaglutide) injection — full prescribing information. Novo Nordisk. Updated 2025. accessdata.fda.gov — Ozempic 2025 label Reference label including the boxed warning, T2DM glycemic control, MACE reduction, CKD indication (per FLOW), severe GI adverse reactions (5.7), and pulmonary aspiration warning (5.10) added in January 2025.
- U.S. Food and Drug Administration. Wegovy (semaglutide) injection and tablets — full prescribing information. Novo Nordisk. Updated 2025/2026. accessdata.fda.gov — Wegovy 2025 label; Wegovy oral 25 mg label Includes weight management (adult and adolescent), MACE reduction in CVD with overweight/obesity, noncirrhotic MASH with F2–F3 fibrosis (added Aug 2025), Wegovy HD 7.2 mg dose (added 2026), and the 25 mg oral tablet dose escalation 1.5 → 4 → 9 → 25 mg every 30 days.
- U.S. Food and Drug Administration. Rybelsus (semaglutide) tablets — full prescribing information. Novo Nordisk. Updated 2025. accessdata.fda.gov — Rybelsus 2025 label Oral semaglutide for T2DM glycemic control and CV risk reduction; includes the 1.5/4/9 mg “formulation R2” tablets and switching guidance with Ozempic.
- U.S. Food and Drug Administration. FDA approves treatment for serious liver disease known as ‘MASH’. August 15, 2025. fda.gov — Wegovy MASH approval announcement Accelerated approval of Wegovy 2.4 mg for noncirrhotic MASH with moderate-to-advanced liver fibrosis based on Part 1 of the ESSENCE trial.
- Novo Nordisk. FDA approves Ozempic (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. January 28, 2025. prnewswire.com — Ozempic CKD approval announcement Source confirming the January 2025 FDA approval of the CKD indication for Ozempic and the FLOW-trial basis.
- Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi.org/10.1056/NEJMoa1607141 SUSTAIN-6 — established cardiovascular safety and superiority of semaglutide for MACE reduction in T2DM with high CV risk; documented increased diabetic retinopathy events (3.0% vs 1.8%; HR 1.76) attributed to rapid A1c lowering in patients with pre-existing retinopathy.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–2232. doi.org/10.1056/NEJMoa2307563 SELECT — established a 20% MACE reduction (HR 0.80; 95% CI 0.72–0.90) with semaglutide 2.4 mg in 17,604 adults with established CVD and overweight/obesity without diabetes; basis for the 2024 Wegovy CV indication.
- Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109–121. doi.org/10.1056/NEJMoa2403347 FLOW — 24% relative risk reduction in the composite kidney/CV outcome with once-weekly semaglutide 1 mg vs placebo in T2DM with CKD; basis for the 2025 Ozempic CKD indication.
- Sanyal AJ, Newsome PN, Kliers I, et al; ESSENCE Investigators. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089–2099. doi.org/10.1056/NEJMoa2413258 ESSENCE Part 1 — at week 72, semaglutide 2.4 mg achieved MASH resolution in 63% vs 34% placebo and fibrosis improvement in 37% vs 22%; basis for the August 2025 Wegovy MASH indication. Part 2 (240 weeks) expected 2029.
- Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Investigators. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi.org/10.1056/NEJMoa2032183 STEP 1 — pivotal weight management trial showing approximately 14.9% mean weight loss with semaglutide 2.4 mg over 68 weeks vs approximately 2.4% placebo.
- Wharton S, Freitas P, Hjelmesæth J, et al; STEP UP Trial Group. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949–963. doi.org/10.1016/S2213-8587(25)00226-8 STEP UP — 20.7% mean weight loss with semaglutide 7.2 mg vs 17.5% with 2.4 mg vs 2.4% placebo over 72 weeks (trial product estimand); supporting evidence for Wegovy HD approval in 2026. Higher rates of dysesthesia at 7.2 mg.
- Wharton S, Lingvay I, Bogdanski P, et al; OASIS 4 Study Group. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077–1087. doi.org/10.1056/NEJMoa2500969 OASIS 4 — pivotal trial of once-daily oral semaglutide 25 mg vs placebo in 307 adults; mean weight loss 13.6% (treatment policy estimand) and 16.6% (trial product estimand); basis for the December 2025 Wegovy oral 25 mg approval.
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–1084. doi.org/10.1056/NEJMoa2306963 STEP-HFpEF — semaglutide 2.4 mg improved KCCQ-CSS, 6-minute walk distance, body weight, and CRP over 52 weeks in 529 patients with obesity-phenotype HFpEF without diabetes. Companion STEP-HFpEF DM trial in T2DM was published in 2024.
- American Diabetes Association. Standards of Care in Diabetes — 2026. Diabetes Care. 2026;49(Suppl 1). professional.diabetes.org/standards-of-care ADA 2026 positions GLP-1 RAs with proven benefit (including semaglutide) as preferred first-line agents in T2DM with established ASCVD, HF, or CKD; recommendations for cardiovascular and renal risk reduction.
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1–S127. doi.org/10.1016/j.kint.2022.06.008 KDIGO recommendation supporting GLP-1 RAs (including semaglutide) for cardiorenal risk reduction in T2DM with CKD; position has been reinforced by FLOW trial data.
- Joshi GP, Abdelmalak BB, Weigel WA, et al. American Society of Anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. ASA. June 29, 2023. asahq.org — 2023 ASA consensus guidance Original 2023 ASA guidance suggesting holding GLP-1 RAs the day before procedures for daily formulations and the week before for weekly SC formulations.
- American Society of Anesthesiologists, American Gastroenterological Association, American Society for Metabolic and Bariatric Surgery, International Society of Perioperative Care of Patients with Obesity, Society of American Gastrointestinal and Endoscopic Surgeons. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. October 2024. asahq.org — 2024 multi-society guidance Updated 2024 guidance softens the original ASA recommendation: most patients can continue GLP-1 RAs before elective procedures, with risk stratification and a 24-hour clear-liquid diet for highest-risk patients.
- Drucker DJ. The benefits of GLP-1 drugs beyond obesity. Science. 2024;385(6706):258–260. doi.org/10.1126/science.adn4128 Authoritative perspective on the expanding indications and mechanisms of GLP-1 receptor agonists across cardiometabolic disease.
- Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021;12:645563. doi.org/10.3389/fendo.2021.645563 Comprehensive safety review covering pancreatitis, gallbladder disease, retinopathy, thyroid considerations, and renal effects.
- Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155. doi.org/10.3389/fendo.2019.00155 Foundational pharmacology paper covering the structural modifications (Aib at position 8, C18 fatty di-acid) that underlie semaglutide’s albumin binding, DPP-4 resistance, and prolonged half-life.